An NCI-designated Comprehensive Cancer Center, affiliated with the University of Pittsburgh School of Medicine
Research
In honor of April being Head and Neck Cancer Awareness Month, we wanted to catch up with Marci Nilsen, PhD, RN, CHPN, FAAN, who we featured a couple years ago and was recently named co-lead for our cancer center’s Biobehavioral…
We are pleased to announce Hong Wang, PhD, as interim director of the Biostatistics Facility and Raman Venkataramanan, PhD, FCP, FAAPS, as interim director of the Cancer Pharmacokinetics and Pharmacodynamics Facility. Dr. Wang has been a biostatistician in the Biostatistics…
We are pleased to announce Marci Lee Nilsen, PhD, RN, CHPN, FAAN, as the new co-lead of UPMC Hillman Cancer Center’s Biobehavioral Cancer Control (BCC) Program, effective March 1, 2025. Dr. Nilsen has been a member of the BCC since…
Benjamin Nacev, MD, PhD, is a recipient of the American Society for Clinical Investigation (ASCI) 2025 Young Physician-Scientist Award. The award recognizes physician-scientists who are early in their first faculty appointment and have made notable achievements in their research. Dr.…
We are pleased to share two exciting announcements for the Genome Stability Program (GSP) at UPMC Hillman Cancer Center. First is the selection of Roddy O’Sullivan, PhD, as the next co-leader of the GSP. In this role, Dr. O’Sullivan will…
Today, the Senior Vice Chancellor for the Health Sciences at the University of Pittsburgh, Anantha Shekhar, MD, PhD, shared the news that Jeremy Rich, MD, MHS, MBA, interim director at UPMC Hillman Cancer Center, has accepted a new role outside…
Please join us in welcoming Natacha De Genna, PhD, to the role of Assistant Center Director for Community Outreach and Engagement (COE) at UPMC Hillman Cancer Center. Dr. De Genna’s role was effective September 1, 2024. She holds appointments as…
This week, Clarivate™ named their list of Highly Cited Researchers for 2024 — an elite group that demonstrates significant and broad influence in their field of research. Each researcher selected has authored multiple Highly Cited Papers™ which rank in the…
Pre-surgery treatment with the novel drug vidutolimod and the PD-1 checkpoint inhibitor nivolumab led to tumor control in 55% of patients with stage 3 cutaneous melanoma, according to the results of a single-arm phase 2 clinical trial led by the…
The results of a recent clinical trial (NCT03743766) published in Cell might pave the way for significant advances in treating advanced melanoma , a serious form of skin cancer. The study, led by University of Pittsburgh and UPMC Hillman Cancer…
